Cat. No. 5035
Chemical Name: 2-Fluoro-4-[[[1,2,3,4-Tetrahydro-1-
Biological ActivitySelective free fatty acid receptor 1 (FFA1/GPR40) agonist. Exhibits selectivity for GPR40 over GPR41, GPR43, GPR119, GPR120 and PPARγ. Induces glucose-dependent insulin secretion in pancreatic MIN6 cells and in vivo. Enhances insulin sensitivity in a type 2 diabetes model in vivo. Orally available.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Tanaka et al (2013) Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion. J.Pharmacol.Exp.Ther. 346 443. PMID: 23853170.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses AS 2034178 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: AS 2034178, supplier, AS2034178, selective, free, fatty, acid, receptors, FFA1, GPR40, agonists, diabetes, insulin, sensitivity, FFAR1, Tocris Bioscience, Free Fatty Acid Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Highly potent P2Y12 antagonistFTY 720
Potent S1P receptor agonist; also immunosuppresentCinacalcet hydrochloride
Calcium-sensing receptor (CaSR) allosteric agonist; also CYP2D2 inhibitor and Ca2+ channel blocker; orally bioavailableAMG 837 hemicalcium salt
Potent free fatty acid receptor 1 (FFA1/GPR40) partial agonistUMB 68
GHB receptor ligandAZD 1283
High affinity P2Y12 antagonistEx 26
Potent and selective S1P1 receptor antagonistZQ 16
Selective GPR84 agonistIHR-Cy3
Potent fluorescent Smo antagonistRo 6842262
Potent LPA1 antagonistAMG 853
Potent dual CRTH2 and prostaglandin D2 (PGD2) receptor antagonistAM 4668
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonist
April 22 - 26, 2017
Chicago, IL, USA